ADVANCES IN COCRYSTALS OF ANTICANCER AGENTS: FORMULATION STRATEGIES AND THERAPEUTIC IMPLICATIONS

Cancer remains one of the most pressing health concerns worldwide, driving continuous efforts in pharmaceutical research to develop more effective treatments. In the ever-evolving landscape of cancer therapy, cocrystals stand as promising contenders, offering enhanced solubility, stability, and bioavailability to traditional anticancer agents. Co-crystallization, a strategy emerging at the nexus of pharmaceutical and crystal engineering. From the fundamental principles of cocrystal engineering to advanced spectroscopic and crystallographic methodologies, each aspect is meticulously dissected to unveil the transformative potential of cocrystals in oncology. The review elucidates the transformative potential of cocrystals in oncology, highlighting their capacity to revolutionize drug delivery and efficacy. Recent advancements in the field are comprehensively examined, showcasing the promising role of anticancer cocrystals in paving the way for novel therapeutic strategies and improved patient outcomes. Cocrystals represent a promising avenue in cancer therapy, offering significant enhancements to traditional anticancer agents. Through a comprehensive exploration of recent advancements, this article navigates the complex terrain of anticancer cocrystals, drug-drug cocrystals, paving the way for novel therapeutic strategies and improved patient outcomes.

Preformulation screening of lipids using solubility parameter concept in conjunction with experimental research to develop ceftriaxone loaded nanostructured lipid carriers

Abstract Development of ceftriaxone loaded nanostructured lipid carriers to increase permeability of ceftriaxone across uninflamed meninges after parenteral administration. Lipids were selected by theoretical and experimental techniques and optimization of NLCs done by response surface methodology using Box-Behnken design. The Δδt for glyceryl monostearate and Capryol90 were 4.39 and 2.92 respectively. The drug had maximum solubility of 0.175% (w/w) in glycerol monostearate and 2.56g of Capryol90 dissolved 10mg of drug. The binary mixture consisted of glyceryl monostearate and Capryol90 in a ratio of 70:30. The optimized NLCs particle size was 130.54nm, polydispersity index 0.28, % entrapment efficiency 44.32%, zeta potential -29.05mV, and % drug loading 8.10%. In vitro permeability of ceftriaxone loaded NLCs was 5.06x10-6 cm/s; evidently, the NLCs pervaded through uninflamed meninges, which, was further confirmed from in vivo biodistribution studies. The ratio of drug concentration between brain and plasma for ceftriaxone loaded NLCs was 0.29 and that for ceftriaxone solution was 0.02. With 44.32% entrapment of the drug in NLCs the biodistribution of ceftriaxone was enhanced 7.9 times compared with that of ceftriaxone solution. DSC and XRD studies revealed formation of imperfect crystalline NLCs. NLCs improved permeability of ceftriaxone through uninflamed meninges resulting in better management of CNS infections.